2023
Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin
Chiang K, Gupta A, Sundd P, Krishnamurti L. Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin. Biomedicines 2023, 11: 338. PMID: 36830874, PMCID: PMC9953430, DOI: 10.3390/biomedicines11020338.Peer-Reviewed Original ResearchSickle cell diseaseVaso-occlusive crisisCell diseaseLipid mediatorsCOVID-19Severe SARS-CoV-2 infectionSARS-CoV-2 infectionSevere COVID-19Platelet-leukocyte adhesionAnti-thrombotic agentsThrombo-InflammationEndothelial injuryRespiratory infectionsSevere illnessClinical trialsThromboxane ATherapeutic strategiesTherapeutic targetPotential treatmentPlatelet activationComplement activationGreater riskClinical researchDiseaseEndothelial cells
2021
A pilot study of the acceptability, feasibility and safety of yoga for chronic pain in sickle cell disease
Bakshi N, Cooley A, Ross D, Hawkins L, Sullivan M, Astles R, Sinha C, Katoch D, Peddineni M, Gee B, Lane P, Krishnamurti L. A pilot study of the acceptability, feasibility and safety of yoga for chronic pain in sickle cell disease. Complementary Therapies In Medicine 2021, 59: 102722. PMID: 33892094, PMCID: PMC8284565, DOI: 10.1016/j.ctim.2021.102722.Peer-Reviewed Original ResearchConceptsProportion of participantsSafety of yogaChronic painSickle cell diseaseYoga sessionsYoga programED visitsMedian ageCell diseasePart ARetention of participantsFeasibility endpointsPain characteristicsPart BPain diaryAdolescent patientsYoga interventionClinical trialsPatient participantsSafety outcomesPainPilot studyMost participantsStudy assessmentYoga
2020
Primary caregiver decision‐making in hematopoietic cell transplantation and gene therapy for sickle cell disease
Sinha C, Bakshi N, Ross D, Loewenstein G, Krishnamurti L. Primary caregiver decision‐making in hematopoietic cell transplantation and gene therapy for sickle cell disease. Pediatric Blood & Cancer 2020, 68: e28749-e28749. PMID: 33034129, PMCID: PMC8246626, DOI: 10.1002/pbc.28749.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantationSickle cell diseasePrimary caregiversSCD complicationsCell transplantationCell diseaseDiminished qualityAutologous hematopoietic progenitor cellsPrimary caregiver reportMajor medical decisionsGene therapyCurative optionSevere complicationsHematopoietic progenitor cellsClinical trialsAcceptable treatmentRecent complicationsComplicationsCaregiver reportsCaregiversProgenitor cellsNormal lifeTransplantationTherapyMedical decisionsAssessment of Patient and Caregiver Attitudes and Approaches to Decision-Making Regarding Bone Marrow Transplant for Sickle Cell Disease
Bakshi N, Katoch D, Sinha C, Ross D, Quarmyne M, Loewenstein G, Krishnamurti L. Assessment of Patient and Caregiver Attitudes and Approaches to Decision-Making Regarding Bone Marrow Transplant for Sickle Cell Disease. JAMA Network Open 2020, 3: e206742. PMID: 32469414, PMCID: PMC7260617, DOI: 10.1001/jamanetworkopen.2020.6742.Peer-Reviewed Original ResearchConceptsBone marrow transplantCaregivers of patientsSickle cell diseasePatient decision aidMarrow transplantMedian ageCurative treatmentCell diseaseGroup 2Group 1Caregiver attitudesNovel disease-modifying therapiesDisease-modifying therapiesSickle cell clinicAssessment of patientsFuture prospective studiesRandomized clinical trialsParent trialProspective studyTreatment optionsClinical trialsNeeds assessment phaseMAIN OUTCOMECell clinicPatients
2019
How I treat sickle cell disease with hematopoietic cell transplantation
Stenger E, Shenoy S, Krishnamurti L. How I treat sickle cell disease with hematopoietic cell transplantation. Blood 2019, 134: 2249-2260. PMID: 31697818, PMCID: PMC6923666, DOI: 10.1182/blood.2019000821.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantationSickle cell diseaseCell transplantationCell diseaseOrgan dysfunctionSCD patientsSignificant morbidityEarly mortalityClinical trialsAvailable cureSCD recipientsAlternative donorsIndividual patientsClinical practicePatientsTransplantationClinical vignettesDiseaseOutcomesMorbidityDysfunctionMortalityTrialsRecipientsEnd points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings
Farrell A, Panepinto J, Desai A, Kassim A, Lebensburger J, Walters M, Bauer D, Blaylark R, DiMichele D, Gladwin M, Green N, Hassell K, Kato G, Klings E, Kohn D, Krishnamurti L, Little J, Makani J, Malik P, McGann P, Minniti C, Morris C, Odame I, Oneal P, Setse R, Sharma P, Shenoy S. End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. Blood Advances 2019, 3: 4002-4020. PMID: 31809537, PMCID: PMC6963248, DOI: 10.1182/bloodadvances.2019000883.Peer-Reviewed Original ResearchConceptsLow-resource settingsEnd pointClinical trial end pointsTrial end pointsPatient-reported outcomesSickle cell disease clinical trialsPanel of cliniciansSickle cell diseaseMeasurement of cureClinical trialsNovel therapiesCell diseaseConsensus recommendationsGlobal burdenUS FoodBiomarker panelDrug AdministrationAvailable evidenceAmerican SocietyCureRelevant findingsLiterature reviewPainPatientsTherapyComparative Effectiveness of a Web-Based Patient Decision Aid for Therapeutic Options for Sickle Cell Disease: Randomized Controlled Trial
Krishnamurti L, Ross D, Sinha C, Leong T, Bakshi N, Mittal N, Veludhandi D, Pham A, Taneja A, Gupta K, Nwanze J, Matthews A, Joshi S, Olivieri V, Arjunan S, Okonkwo I, Lukombo I, Lane P, Bakshi N, Loewenstein G. Comparative Effectiveness of a Web-Based Patient Decision Aid for Therapeutic Options for Sickle Cell Disease: Randomized Controlled Trial. Journal Of Medical Internet Research 2019, 21: e14462. PMID: 31799940, PMCID: PMC6934048, DOI: 10.2196/14462.Peer-Reviewed Original ResearchConceptsRandomized clinical trialsPatient decision aidSickle cell diseaseWeb-based patient decision aidClinical trialsHealth care providersCell diseaseDecisional conflictPatient knowledgeCare providersDecision aid armStandard care armOttawa Decision Support FrameworkChronic blood transfusionsDisease-modifying therapiesBone marrow transplantationDecision aidCare armDecision aid prototypeClinical characteristicsBlood transfusionControlled TrialsPediatric patientsMarrow transplantationTherapeutic options
2017
Novel Metrics in the Longitudinal Evaluation of Pain Data in Sickle Cell Disease
Bakshi N, Smith M, Ross D, Krishnamurti L. Novel Metrics in the Longitudinal Evaluation of Pain Data in Sickle Cell Disease. The Clinical Journal Of Pain 2017, 33: 517-527. PMID: 27584817, DOI: 10.1097/ajp.0000000000000431.Peer-Reviewed Original ResearchConceptsMaximum daily painSickle cell diseasePain intensity dataChronic painCell diseasePain dataInterindividual variationMaximum daily pain scoresPatient-reported end pointsDaily pain scoresPain-free daysInterventional clinical trialsBurden of painPeriod of hospitalizationElectronic pain diaryDiary daysHealth care providersPain burdenPain scoresPain diaryPain intensityDaily painSCD patientsPain trendsClinical trials
2015
Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantation
Stenger E, Krishnamurti L, Galipeau J. Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantation. BMC Immunology 2015, 16: 74. PMID: 26674007, PMCID: PMC4681052, DOI: 10.1186/s12865-015-0135-7.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantationMesenchymal stromal cellsCell transplantationPost-hematopoietic cell transplantationStromal cellsHematopoietic stem cell engraftmentPre-clinical studiesStem cell engraftmentHost diseaseImmune reconstitutionClinical trialsAnimal modelsCell engraftmentMultipotent progenitor cellsImmune systemHSC engraftmentCellular therapyProgenitor cellsTransplantationEngraftmentTrialsDual effectCellsEarly evidenceGVHD
2014
Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial
Helton KJ, Adams R, Kesler K, Lockhart A, Aygun B, Driscoll C, Heeney M, Jackson S, Krishnamurti L, Miller S, Sarnaik S, Schultz W, Ware R, Investigators F. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood 2014, 124: 891-898. PMID: 24914136, PMCID: PMC4126329, DOI: 10.1182/blood-2013-12-545186.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnemia, Sickle CellBlood Flow VelocityBlood TransfusionBrainCerebrovascular CirculationChildChild, PreschoolFemaleFunctional NeuroimagingHumansHydroxyureaMagnetic Resonance AngiographyMagnetic Resonance ImagingMalePrognosisSecondary PreventionStrokeUltrasonography, Doppler, TranscranialYoung AdultConceptsMagnetic resonance imaging/magnetic resonance angiographyVessel stenosisWorse stenosisMagnetic resonance imaging/Central blinded reviewNew silent infarctTranscranial Doppler examsTransient ischemic attackFuture clinical trialsTranscranial Doppler velocitiesMagnetic resonance angiographySickle cell anemiaHydroxyurea trialIschemic attackRecurrent strokeSilent infarctsCerebrovascular injuryParenchymal injuryChronic transfusionTCD velocitiesSevere baselineDoppler examVascular abnormalitiesClinical trialsIron overload
2011
Clinical trial implementation and recruitment: Lessons learned from the early closure of a randomized clinical trial
Peters-Lawrence M, Bell M, Hsu L, Osunkwo I, Seaman P, Blackwood M, Guillaume E, Bellevue R, Krishnamurti L, Smith W, Dampier C, Minniti C, Network F. Clinical trial implementation and recruitment: Lessons learned from the early closure of a randomized clinical trial. Contemporary Clinical Trials 2011, 33: 291-297. PMID: 22155024, PMCID: PMC3577351, DOI: 10.1016/j.cct.2011.11.018.Peer-Reviewed Original ResearchConceptsNew England Research InstituteClinical trialsRandomized clinical trialsFuture clinical trialsClinical trial implementationComplex dosing schedulesClinical Research NetworkPatient Controlled AnalgesiaProtocol acceptanceSCD clinicPain controlPain crisisAcute painDosing schedulesAcute interventionOutside physiciansUrgent careEligibility criteriaEnrollment periodPatient encountersEarly closurePainRecruitment barriersTrialsStaff availability
2010
Chronic Pain Is An Independent Predictor of Lower 6 Minute Walk Distance In Patients with Sickle Cell Disease: Results From Walk-PHaSST Study
Krishnamurti L, Goel R, Castro O, Barst R, Rosenzweig E, Sachdev V, Machado R, Gibbs S, Little J, Schraufnagel D, Girgis R, Morris C, Badesch D, Lanzkron S, Goldsmith J, Gordeuk V, Kato G, Gladwin M, Hassell K. Chronic Pain Is An Independent Predictor of Lower 6 Minute Walk Distance In Patients with Sickle Cell Disease: Results From Walk-PHaSST Study. Blood 2010, 116: 2658. DOI: 10.1182/blood.v116.21.2658.2658.Peer-Reviewed Original ResearchTricuspid regurgitant velocityAcute pain crisisSickle cell diseasePain crisisChronic painExercise capacityIndependent predictorsClinical trialsCell diseaseAcute sickle cell pain crisisSickle cell pain crisisMultivariable logistic regression analysisSickle cellsAcute pain ratingsHypertension clinical trialsTrials of sildenafilDouble-blind placeboEmergency department visitsGroup of patientsMinute walk distanceWeeks of treatmentNon-drug therapyFuture clinical trialsSignificant lower odds ratioLogistic regression analysis